C/EBPα in multiple myeloma patients may lead to increased hepcidin.
10.7534/j.issn.1009-2137.2014.05.025
- Author:
Xiao HAN
1
;
Dao-Bin ZHOU
2
;
Ming-Hui DUAN
1
;
Bao-Lai HUA
1
;
Xuan WANG
1
;
Jie-Ping ZHANG
1
;
Yong-Qiang ZHAO
1
;
Ti SHEN
1
;
Yong-Ji WU
1
Author Information
1. Department of Hematology, Peking Union Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
2. Department of Hematology, Peking Union Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China. E-mail: daobinzhou@yahoo.com.
- Publication Type:Journal Article
- MeSH:
Anemia;
CCAAT-Enhancer-Binding Protein-alpha;
metabolism;
Chronic Disease;
Hepcidins;
metabolism;
Humans;
Interleukin-6;
Monocytes;
Multiple Myeloma;
metabolism;
RNA, Messenger;
Up-Regulation
- From:
Journal of Experimental Hematology
2014;22(5):1316-1320
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to explore the possible mechanisms of hepcidin increase in multiple myeloma patients. The clinical information and peripheral venous blood of eligible patients with previously untreated multiple myeloma were collected. Serum concentration of IL-6 was detected by ELISA. Peripheral blood monocytes were isolated by CD14⁺ magnetic beads. The expression of hepcidin, IL-6 and C/EBPα mRNA of monocytes were detected by real time quantitative PCR. The results indicated that the hemoglobin level was reduced in 17 multiple myeloma patients enrolled in study (97.8 ± 27.5 g/L), showing the characteristics of anemia of chronic disease. The hepcidin and C/EBPα expression of peripheral blood monocytes significantly increased (P < 0.01), serum IL-6 was also higher than that in normal controls (P < 0.01). Serum IL-6 positively correlated with monocyte hepcidin and C/EBPα expression (P < 0.05); monocyte C/EBPα expression positively correlated with monocyte hepcidin expression (P < 0.05). It is concluded that the elevated IL-6 may induce hepcidin expression through up-regulating C/EBPα in untreated myeloma patients.